IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for COVID-19

The agreement is "to develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic", the partners said in a statement on Thursday.

from Lifestyle News:Entertainment News,Bollywood Latest News,Box Office Collection Report,Movie Reviews
Read The Rest:financialexpress...